On October 1, 2026, SpyGlass Pharma, a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions, announced the acquisition of all outstanding shares of Advanced Vision Science (AVS), an ophthalmic medical device company and manufacturer of intraocular lenses (IOLs) and lens materials, for approximately $13 million dollars in cash. This acquisition secures scalable commercial IOL manufacturing capacity for SpyGlass Pharma for its Phase 3 lead product candidate (the BIM-IOL System) and accelerates pathway to adding premium lens options into its IOL-based drug delivery system. Wilson Sonsini Goodrich & Rosati advised SpyGlass Pharma on the transaction.
The Wilson Sonsini team that advised SpyGlass Pharma on the transaction included:
Corporate
Dan Koeppen
Robert Wernli
Bridget Balisy
Mergers and Acquisitions
Catherine Riley Tzipori
Jason Breen
Orlando Hodges
Technology Transactions
Lowell Segal
Shefali Lumb
Gopika Das Mesrobian
Employee Benefits and Compensation
Matthew Norgard
Real Estate
Susan Reinstra
Paige Baker
Regulatory
Eva Yin
For more information, please see SpyGlass Pharma's news release.